Cytogen (Korea) Today
| 217330 Stock | KRW 9,220 230.00 2.43% |
Performance0 of 100
| Odds Of DistressLess than 30
|
Cytogen is trading at 9220.00 as of the 12th of June 2024, a -2.43 percent decrease since the beginning of the trading day. The stock's open price was 9450.0. Cytogen has about a 30 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Cytogen are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 15th of December 2023 and ending today, the 12th of June 2024. Click here to learn more.
Cytogen, Inc., a biotechnology company, develops and sells CTC enrichment and downstream systems to treat cancer in South Korea. Cytogen, Inc. was founded in 2010 and is headquartered in Seoul, South Korea. Cytogen is traded on Korean Securities Dealers Automated Quotations in South Korea.. The company has 5.63 M outstanding shares. More on Cytogen
Moving together with Cytogen Stock
Moving against Cytogen Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cytogen Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Cytogen's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Cytogen or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology & Medical Research, Healthcare (View all Sectors) |
Cytogen (217330) is traded on KOSDAQ in Korea . The company currently falls under 'Large-Cap' category with a current market capitalization of 95.89 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cytogen's market, we take the total number of its shares issued and multiply it by Cytogen's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cytogen operates under Healthcare sector and is part of Biotechnology & Medical Research industry. The entity has 5.63 M outstanding shares.
Cytogen has accumulated about 30.29 B in cash with (5.23 B) of positive cash flow from operations.
Check Cytogen Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cytogen is W95.89 Billion. Cytogen retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cytogen Ownership Details
Cytogen Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cytogen market risk premium is the additional return an investor will receive from holding Cytogen long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cytogen. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Cytogen's alpha and beta are two of the key measurements used to evaluate Cytogen's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.6 | |||
| Standard Deviation | 3.46 | |||
| Variance | 11.97 | |||
| Risk Adjusted Performance | (0.09) |
Cytogen Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cytogen without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Other Information on Investing in Cytogen Stock
Cytogen financial ratios help investors to determine whether Cytogen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cytogen with respect to the benefits of owning Cytogen security.